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Several different agonists of the retinoic X receptor  (hRXR) were examined for their effects on
the amide H/D exchange kinetics of the homodimeric protein using mass spectrometry. Some
agonists, LG 100268, SR11246, and DHA, bind such that slower deuterium exchange-in occurs
compared with 9-cis-retinoic acid (9-cis-RA), whereas others, fenretinide and methoprenic acid,
result in poorer protection during binding and hence faster exchange-in. Protection against H/D
exchange by different agonists and the inhibition of H/D exchange kinetics relative to 9-cis-RA
varies markedly in different regions of the protein. Agonists LG 100268, SR11246, and DHA
generally inhibit faster exchange processes in the ligand binding regions of hRXR than does the
native ligand 9-cis-RA. In at least half of these regions, the level of protection by 9-cis-RA lags
behind the agonists even after 60 min. Methoprenic acid did not significantly protect hRXR
against amide hydrogen exchange. An efficient method is described for comparing the effects of
different agonists on the protein structure of the agonist-RXR complex. (J Am Soc Mass
Spectrom 2006, 17, 1510–1517) © 2006 American Society for Mass SpectrometryThe retinoid X receptors (RXRs) belong to a familyof nuclear receptors that play important roles indevelopment, metabolism, and cellular ho-
meostasis [1, 2]. RXRs are activated by several naturally
occurring or synthetic retinoids that, by binding to the
ligand-binding domain (LBD), induce conformational
changes that cause activator association and initiation
of the transcription of the genes regulated by a tran-
scription factor [1, 2]. RXR or its dimeric partner func-
tioning as RXRs can exist and function as homodimers
or heterodimers with preferred partners from among
other members of the nuclear hormone receptor family
[3]. Therefore, RXRs and their ligands have critical roles
in modulating many diverse signaling pathways.
Among the three RXR isotypes (, , and ), RXR is
the primary receptor during development, and its bio-
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[4]. Recently, studies have shown that synthetic RXR
agonists may have potential as therapeutics for a range
of diseases including cancer, diabetes, cardiovascular
disease, and obesity [5–7]. In addition, there is evidence
suggesting that highly selective binding by synthetic
retinoids to RXRs may reduce adverse effects in the
treatment of diseases [8]. Thus, RXR has emerged as
an important therapeutic target for synthetic agonists.
Structural studies have revealed a basic mechanistic
picture by which ligands regulate RXR activity, i.e.,
interaction of ligands leads to large conformational
changes in the protein that drive dissociation of co-
repressor molecules and the recruitment of coactivator
molecules by the newly created interaction surface
resulting from helix 12 movement [9, 10]. As shown by
the X-ray structure, some synthetic ligands, such as LG
100268, can occupy the RXR binding pocket but cause
helix 12 to adopt an altered position compared with
9-cis-RA, so that corepressor release fails in the absence
of the coactivators. Experiments using two hybrid anal-
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Figure 1. Chemical structures of the hRXR LBD agonists.
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absence of coactivator, and that the coactivator and
agonist must bind to stabilize helix 12 in the active
conformation. X-ray crystallography and nuclear mag-
netic resonance (NMR) are well recognized as provid-
ing the highest resolution structural information on
proteins and protein-ligand complexes, but these meth-
ods are limited either because suitable crystals cannot
be obtained for X-ray analysis or the amount of protein
available is insufficient for characterization by NMR.
Hydrogen/deuterium (H/D) exchange coupled with
analysis by mass spectrometry is a useful alternative to
these methods because the crystalline protein is unnec-
essary and sensitivity is not nearly the limiting factor
that it is with NMR.
A previous study using H/D exchange mass spec-
trometry on the recombinant human RXR ligand-
binding domain (hRXR LBD) yielded results that were
consistent with the information provided by X-ray
analysis with regard to the regions of the protein that
contact the ligand 9-cis-RA. Furthermore, the H/D
exchange mass spectrometric approach provided infor-
mation that is not obvious from X-ray analysis on the
protection of amide hydrogens from exchange in re-
gions that are not directly in contact with bound
9-cis-RA [12]. In the present study, the interactions of
the hRXR LBD homodimer with several agonists (Fig-
ure 1) were explored using H/D exchange mass spec-
trometry. Agonist-free protein and 9-cis-RA-bound pro-
tein were used as controls. The results from these
studies may contribute to an understanding of the
biological functions and mechanisms of the interaction
between the RXR LBD and these agonists that could be
useful in drug discovery and drug development for
improved treatments of associated diseases.
Experimental
Materials and Reagents
Deuterium oxide (D2O; 99.9% deuterium), porcine
pepsin, and trifluoroacetic acid (TFA) were pur-
chased from Sigma-Aldrich Chemical Co. (St. Louis,
MO). 3-[(3-Cholamidopropyl)dimethyl-ammonio]-1-
propanesulfonate (CHAPS) and tris(2-carboxyethyl)
phosphine hydrochloride (TCEP) were obtained from
Pierce (Rockford, IN). Poros 20 AL media was purchased
from Applied Biosystems (Foster City, CA). The hRXR
agonists, 9-cis retinoic acid (9-cis-RA), methoprenic acid
(98%), cis-4,7,10,13,16,19-docosahexenoic acid (DHA)
(98%) were purchased from Sigma-Aldrich Chemical
Co., fenretinide (95%) was purchased from Tocris (Ellis-
ville, MO). LG 100268 was from Ligand Pharmaceuticals
and SR11246 was prepared by one of us (MID). All
agonists were prepared as 10 mM stock solutions in
ethanol. All other materials were reagent grade and ob-
tained from standard commercial sources.
The hRXR LBD was expressed and purified as
described preciously [12], and confirmed as a ho-
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TCEP, and 50 mM potassium phosphate, pH 7.4) by
size-exclusion chromatography and mass spectrometry
[12]. The deuterium exchange-in experiments were per-
formed using a homodimer concentration of 45 M (or
hRXR monomer concentration of 90 M) stock solu-
tion in aqueous buffer. The buffer (H2O or D2O) con-
sisted of 0.5 M KCl, 0.5 mM CHAPS, 1 mM TCEP, and
50 mM potassium phosphate buffer (pH 7.4).
PDB Structure Analysis
Protein-ligand contact information was derived using a
web site-based program LPC/CSU [13] at http://ligin.
weizmann.ac.il/space/servers/ and 3D figures were
generated by Pymol. Protein secondary structure was
determined by the DSSP program [14].
Sequence alignment analysis was carried out by the
web site-based program ClustalW at http://www.ebi.
ac.uk/clustalw/. Virtual hydrogen bonding sites were
identified using the HBPlus 3.15 program [15].
Hydrogen/Deuterium Exchange and Digestion
Protein-ligand equilibration was achieved by adding1
L agonist stock solution (10 mM, or 1 L ethanol as
blank) to 35 L homodimer hRXR LBD (45 M) and
incubating for 30 min (agonist/monomeric protein mo-
lar ratio was over 3:1). The small amount of ethanol
(2.8% vol/vol) did not affect protein binding as indi-
cated by CD titration data. Before deuterium exchange-
in, the D2O buffer, in which the same percentage of
agonist and/or ethanol was added, was equilibrated at
30 °C. Deuterium exchange-in was initiated by combin-
ing the protein solution (20 L) with D2O buffer (200
L) at 30 °C. Since the dissociation constants for ligands
are in the nanomolar range and the final concentration
of binding sites was nearly 10 M after dilution, it was
assumed that all ligand binding sites were occupied.
After 0.25, 1, 2, 3, 5, 10, 30, and 60 min, aliquots (20 uL)
were taken and added to a prechilled tube containing 20
L of 0.42% phosphoric acid to quench the reaction (pH
2.5). The quenched sample was immediately divided
into two tubes and frozen in liquid nitrogen for dupli-
cate LC-ESI-MS analysis later.
The protein was eluted within 6 min through a C4
column (0.32 50 mm, Vydac, 10 m, in-house packed)
with a steep gradient (mobile phase A: 0.04% TFA in
H2O, mobile phase B: 0.04% TFA in CH3CN). For intact
protein analysis the column was coupled directly to the
mass spectrometer. On-line proteolytic digestion was
carried out within 3 min under quench conditions (0 °C
and pH 2.5), using an in-house prepared immobilized
pepsin column as detailed by Wang [16]. The peptic
peptides were captured on a C18 trap (1  8 mm,
Michrom Bioresources, Inc., Auburn, CA), then further
separated through a C18 column (0.32  100 mm, Luna
C18(2), 5 , in-house packed) before delivery into the
mass spectrometer within 9 min, using the same elutionsolvent as described above. The entire apparatus (injec-
tor, enzyme column, C18 trap, C18 column, and part of
the solvent transfer tubing for delivery into the mass
spectrometer) was immersed in an ice bath.
Mass Analysis and Data Processing
For MS experiments, spectra on the intact protein were
acquired with an LCT mass spectrometer (Waters
Corp., Millford, MA) that was equipped with a stan-
dard ESI source. All mass spectral measurements were
taken with the following settings and conditions: cap-
illary voltage 3 kV, sample cone voltage 60 V, extraction
cone voltage 5 V, source temperature 80 °C, desolvation
temperature 120 °C, desolvation gas 500 L/h. The intact
protein molecular weight (deuterated and nondeuter-
ated sample) was obtained by deconvoluting the com-
bined ESI spectra of the protein with MaxEnt1 of the
MassLynx 4.0 program (Waters). The centroided mass
of peptic peptides (see below) (deuterated and nondeu-
terated samples) was calculated from the ESI spectra of
the peptide with the Magtran program (Zhongqi
Zhang, Amgen, Thousand Oaks, CA). The deuterium
levels for protein or peptic peptides were determined
from the mass difference between the deuterated and
nondeuterated samples. A mass difference of 0.3 Da
was not considered to be a significant difference in H/D
exchange in the present study.
Pepsin-generated peptides were identified through
the data-dependent MS/MS mode with dynamic exclu-
sion spectra acquired by the LCQ instrument and
SEQUEST database search engine against the sequences
of the protein and pepsin for assignments. All peptide
Figure 2. Deuterium levels observed at amide bonds in the
subunit of the homodimer hRXR LBD with and without agonist
binding as a function of deuterium exchange-in time from 0.25
min to 60 min (agonist-free protein, open diamond; 9-cis-RA-
protein complex, open square; methoprenic acid-protein complex,
open circle; fenretinide-protein complex, filled circle; DHA-pro-
tein complex, open triangle; LG 100268-protein complex, filled
diamond; protein-SR11246 complex, filled triangle).ion assignments were further verified manually.
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Back-exchange of the hydrogen isotope in both protein
and peptic fragments was estimated from the difference
of the theoretical mass for the fully deuterated protein
or peptides (0% loss) and the experimentally measured
mass of the fully deuterated sample. The fully deuter-
ated protein was obtained by denaturing the protein in
D2O buffer containing 7 M urea-d4 and allowing
exchange-in for 5 h at room temperature, and then
renaturing the protein in D2O buffer by removing
urea-d4 using a Biomax membrane ultrafilter (Milli-
pore Corp., Bedford, MA).
It was not considered necessary to adjust for deute-
rium back-exchange when comparing the effects of
various agonists on the same peptide or protein, as the
back-exchange should be similar under identical condi-
tions. However, minimizing back-exchange was consid-
ered important to avoid losing important deuterium
exchange information and to show the greatest possible
differences from ligand interactions. In the present
study, the back-exchange for the peptides varied be-
tween 15 and 38% depending on their sequence and LC
retention time during separation; the average back-
exchange for the peptides was 29%. The back-exchange
for the intact protein was 8.7%.
Results and Discussion
It was shown previously by H/D-MS and kinetic anal-
ysis that the naturally occurring full agonist 9-cis-RA,
when bound to the homodimer of hRXR LBD, exhib-
Figure 3. Effects of agonist binding on the deu
to residues 271–278, 310–319, 419–425, and
(agonist-free protein, open diamond; 9-cis-RA-p
plex, filled triangle; LG 100268-protein complex
circle; DHA-protein complex, open triangle; m
correction was made for proton back-exchange.ited protection against deuterium exchange-in in theligand binding pocket, mainly within the region of helix
3, the two -sheets, helix 5, and the carboxyl terminus
segment of helix 11. Protection was also found in
regions that did not involve direct contact between the
protein and the ligand [12]. In the present study,
agonists bound to the homodimer of hRXR LBD
triggered similar conformational changes; the interac-
tion specificity was investigated by the same approach.
The agonist-free protein and 9-cis-RA-bound protein
were used as controls for comparison.
The deuterium level observed in the intact protein as
a function of time illustrated a straightforward picture
of the influence of these bound agonists on protein
backbone amide H/D exchange kinetics (Figure 2).
Only a slight protection against deuterium exchange-in
was observed for bound methoprenic acid compared
with that observed for agonist-free protein, while 9-cis-
RA-like protection was observed from binding by ago-
nists SR11246 and fenretinide, and greater protection
resulted from agonist LG 100268 binding. The mass
spectrum from DHA-bound protein that had under-
gone H/D exchange consisted of diffuse peaks at each
charge state, which were not amenable to transforma-
tion. From these spectra, no evidence for distinct con-
formers could be gleaned, but rather a broad nonspe-
cific distribution of deuterium in the DHA-bound
protein was observed. Fortunately, the labeled peptides
from DHA-RXR LBD could be analyzed as described
below.
The peptic map used in this study was slightly
different than the one described previously [12] because
exchange-in rates in fragments corresponding
438 of the protein hRXR LBD homodimer
n complex, open square; protein-SR11246 com-
d diamond; fenretinide-protein complex, filled
prenic acid-protein complex, open circle). Noterium
431–
rotei
, fille
ethodigestion was carried out on-line. Nevertheless, se-
discussed in the text.
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the peptic peptides from the agonist-free protein, all
investigated agonists except fenretinide and metho-
prenic acid reduced the deuterium incorporation rate as
evident from the analysis of the peptides corresponding
to those previously identified from binding of 9-cis-RA
[12]. The degree of protection and H/D exchange
kinetic profiles, however, varied considerably as illus-
trated by the results obtained for peptic peptides corre-
sponding to residues 271–278, 310–319, 419–425, and
431– 438 (Figure 3). The fragment corresponding to
residues 271–278 contains three binding residues (Fig-
ure 4, bolded AA’s) as shown by crystallographic
analysis of the 9-cis-RA-protein complex. This fragment
exhibited a significant decrease at the early time points
(30 min) in the amount of deuterium incorporation
when 9-cis-RA bound to the protein in the time course
study [12]. Slight protection in deuterium exchange-in
was observed for this fragment when agonist fenretin-
ide bound to the protein. The greatest decrease in
deuterium incorporation in this fragment occurred on
formation of the complex with the agonist LG 100268 or
DHA to suggest that more amide hydrogen atoms are
protected against exchange-in in the presence of these
agonists compared with 9-cis-RA. The observed protec-
tion may arise from steric factors or from ligand inter-
action with specific backbone amide hydrogens; how-
ever, it could also arise from an alteration of the protein
backbone dynamics in this region. The 9-cis-RA-like
reduction in deuterium exchange-in in residues 271–278
in the presence of agonist SR11246 occurred within the
Figure 4. Structure resolved complexes LG 10
hRXR LBD (PDB entry: 1fby) sequence align
proteins. Bold characters represent the contact
LPC/CSU program analysis. Residues are numb
The twelve -helical regions are marked for hRX
entry: 1lbd).Figure 5. Close-up image of agonist-protein interface in which
dashed lines indicate contact atoms. (a) Comparison of hydropho-
bic interactions of LG 100268 and 9-cis-RA in host protein. The
hydrophobic interaction of the cyclopropyl ring in LG 100268
(orange) in the complex hRXR-LG 100268 (left) is mainly with
Leu380 (red) and Ile381 (blue). The same residues in hRXR
(Leu309 in red, and Ile310 in blue), showing the hydrophobic
interaction is mainly provided by the methyl group and C8, C9,
and C10 in 9-cis-RA (orange) in the complex 9-cis-RA-hRXR
(right). (b) Agonist (orange) contacts to Ser383 (red), Phe384
(blue), and Arg387 (purple) in LG 100268-hRXR complex (left),
and to Ser312 (red), Phe313 (blue), and Arg316 (purple) in 9-cis-
RA-hRXR (right) binding pockets. These residues are located in
the fragment that corresponds to residues 310–319 in hRXR LBD,0268-hRXR LBD (PDB entry: 1h9u) and 9-cis-RA-
ment to exhibit the similarities between these two
ed sites for the agonist in each complex based on
ered according to the human sequence of the protein.
R based on their agonist free crystal structure (PDB
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greater than that observed for 9-cis-RA, again resulting
in slower deuterium exchange kinetics. The deuterium
incorporation level for this fragment indicated that the
methoprenic acid-hRXR complex, if it existed at all,
was only very weakly associated at this site.
Significantly lower deuterium levels were observed
in the peptide corresponding to residues 310–319, as
was the case previously observed in the 9-cis-RA-
hRXR complex [12]. Three residues, Ser312, Phe313,
and Arg316, (Figure 4) in this fragment directly contact
the ligand 9-cis-RA in the crystal structure of this
complex (PDB entry: 1fby). Two types of protection
were observed for deuterium exchange-in by other
agonists. First, fenretinide and methoprenic acid
showed protection of this fragment similar to that
found for 9-cis-RA. Second, deuterium exchange-in to
this fragment was even further reduced when LG
100268, SR11246, or DHA was bound to the protein.
Previous SAR studies with synthetic analogs of RXR
ligands suggested that cancer prevention was based on
drug selectivity for specific retinoid receptor subtypes
[17]. Thus, the hydrophobic character of the ligands was
increased on the bridge linking the aromatic and cyclo-
hexene rings of these agonist structures. The selectivity
for RXR was further enhanced through a cyclopropyl
ring that was designed into the SR11246 and LG 100268
structures to replace the carbon bridge present in the
earlier agonists [17]. The resolved crystal structure of
the LG 100268-RXR complex was acquired for the RXR
LBD (PDB entry: 1h9u), but since the -subtype shares
89% of its sequence with the protein used in the present
study, the binding residues are assumed to be almost
the same in both complexes (Figure 4). Therefore, the
known interaction between LG 100268, which is specific
for RXRs but not RARs (retinoic acid receptors) and
hRXR LBD can be used as a model for binding of LG
100268 to the hRXR LBD in the present study. The two
carbons in the cyclopropyl ring of the LG 100268
structure mainly contact Leu380 and Ile381 in hRXR
LBD (Figure 5a, left), which correspond to Leu309 and
Ile310 in hRXR LBD. In the 9-cis-RA-hRXR complex
the ligand binds through its methyl group and C8, C9
and C10 to these residues in the receptor (Figure 5a,
right). The crystal structure indicates that in addition to
these two hRXR residues three others, Ser383, Phe 384,
and Arg387, are in contact with the ligand. These
correspond to Ser312, Phe313 and Arg316, respectively,
in hRXR for contacts with ligands LG 100268 and
9-cis-RA, (Figure 5b). The hydrogen bonding status of
the amide hydrogens in the peptic fragment corre-
sponding to residues 310–319 in hRXR LBD would be
the same as those in its complexes with LG 100268 and
9-cis-RA, as suggested by computational results from
the HBPlus program. The reduction in deuterium incor-
poration in this fragment upon binding agonists follows
the order SR11246 and DHA  LG 100268  9-cis-RA,
fenretinide, and methoprenic acid (Figure 3). Thus, the
trend appears to correlate with the increase in hydro-phobic interactions inherent in the agonist structures
that modified the amide hydrogen bonding network of
the interacted regions of the protein and/or shield the
protein amide hydrogens from the solvent.
Similarly, reduced deuterium incorporation was
observed in the fragment corresponding to residues
431–438, which also contains three X-ray crystallo-
graphic contact residues, Cys432, His435, and Leu436
(Figure 4). However, lower protection against H/D
exchange appears only in the early time points for
9-cis-RA and most of the agonists, in the complexes
with hRXR. The initial increased protection in this
peptide as well as in peptide 271–278 towards deute-
rium exchange-in by different agonists relative to that
observed in peptide 310–319, shows that agonists
affect the exchange rates differently in different re-
gions of the protein. The agonist methoprenic acid
exhibited limited or no H/D exchange protection in
Figure 6. Deuterium exchange-in protection through agonist
binding to hRXR LBD homodimer relative to 9-cis-RA binding as
shown in the peptic peptides. The difference in deuterium content
between the hRXR-agonist and hRXR-9-cis-RA is exhibited at
eight different time points (0.25, 1, 2, 3, 5, 10, 30, and 60 min, left
to right) for each peptic fragment as a series of vertical bars. The
nonprotected regions are not shown (a) LG 100268; (b) fenretinide;
(c) SR11246; (d), DHA; (e) methoprenic acid).fragment 431–438. LG 100268 exhibited the greatest
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and DHA showed extended protection over time
(Figure 3). In peptic fragment 419 – 425, the agonists
generally showed less protection towards deuterium
exchange-in compared with 9-cis-RA, and a generally
constant kinetic pattern of exchange over the time
course that revealed a lower degree of conforma-
tional perturbation for different agonists compared
with 9-cis-RA. Overlapping fragments may help to
increase the resolution for locating the conformation-
ally changed sites. In the case of methoprenic acid,
the fragment corresponding to residues 347–353 from
the complex showed no deuterium level changes
compared with that from the 9-cis-RA complex, but
the deuterium level increased in the fragment corre-
sponding to residues 348–353. These results indicate
that amide hydrogens near Arg348, which is sur-
rounded by three residues that interact with bound
agonist (Figure 4), is less protected by methoprenic
acid than by 9-cis-RA.
Analysis of differences in deuterium content in the
homodimer hRXR LBD resulting from complexation
with 9-cis-RA and that found with other agonists fur-
ther reveals the comparative rates of amide hydrogen
exchange that are affected by different ligands (Figure
6). These exchange differences vary from one region of
the protein to another and indicate different types of
ligand-induced conformational ensembles. An analysis
of the effects of each agonist on amide hydrogen
exchange in different sequences of the receptor is facil-
itated by relating the exchange behavior to the native
ligand 9-cis-RA (Figure 6). This comparison immedi-
ately reveals the overall effectiveness of the agonists at
protecting against deuterium exchange-in. Thus,
throughout most of the ligand-binding domain, it is
immediately obvious that agonists LG 1000268,
SR11246, and DHA are superior to 9-cis-RA at protect-
ing the receptor against amide hydrogen exchange,
whereas fenretinide and methoprenic acid are generally
seen to be less effective. All of the peptic fragments
except those within the sequence 234–248 contain one
or more ligand-binding residues (Figure 4). The results
for these fragments also reveal whether a given agonist
when compared with 9-cis-RA affects deuterium ex-
change-in and thus the conformational ensembles in a
given region of the protein.
The -helix 12 is a key structural motif for cellular
function and regulation in RXR and exhibits extreme
flexibility as reveled in both a previous study[12] and
the present studies. Despite the dramatic movement of
this segment upon binding by 9-cis-RA, the H/D ex-
change kinetics were essentially unaffected and no
deuterium exchange difference was observed in helix 12
in the presence or absence of 9-cis-RA. A change in
H/D exchange kinetics in this segment, however, was
observed on complexation by the other agonists (Figure
6). For example, the N-terminal region of helix 12,
which was represented by the fragment corresponding
to residues 439–449 apparently showed increased deu-terium incorporation when RXR associated with metho-
prenic acid. A slight increase in deuterium incorpora-
tion was also observed in this fragment upon binding
by LG 100268 and SR11246. H/D exchange kinetics in
the C-terminal region of helix 12 was not modified by
any of these agonists (data not shown), which is con-
sistent with the structural analysis in that agonists do
not strongly affect the conformation of the C-terminal
region [18]. This unique behavior of helix 12 in deute-
rium exchange incorporation in the complexes with LG
100246 and SR11246 may be related to the altered
positions of helix 12, which resulted in RXR’s failure to
release the corepressors. No direct information is avail-
able for methoprenic acid regarding corepressor release
although the observation that the retinoic acid metabo-
lite acts as an agonist in cultured cells [1] suggest that
corepressor-coactivator exchange does take place in
vivo.
Structurally similar agonists, like LG 100268 and
SR11246, which differ only in a methyl group in one
aromatic ring and a pyridine ring substituted for a
benzene ring (Figure 1), result in very similar amide
deuterium exchange kinetic patterns throughout the
protein backbone (Figure 6a and c). Clearly, in com-
parison with the ligand 9-cis-RA, these two agonists
cause a significant decrease in the deuterium incor-
poration in almost all of the hRXR LBD H/D
exchanging sites. Since all ligands have dissociation
constants in the nM range, they are saturating at M
concentrations of protein and ligand. Thus, the pro-
tection may arise from an increased complex lifetime,
increased hydrogen bonding to exchangeable back-
bone amides, an altered protein conformation, or a
protein conformation unique to these ligands. The
deuterium incorporation of fenretinide or metho-
prenic acid shows some similarity to that of 9-cis-RA
as ligand, the most important of which is that in
almost all peptides from the hRXR LBD, the amide
deuterium levels were greater. Structurally, there
also are similarities in these two compounds, most
notably the isoprenoid motif that serves as the back-
bone. RXR is reportedly activated in human cells by
this metabolite of the pesticide, methoprene [19], and
high doses have been shown to cause teratogenic
effects during mouse embryogenesis [20]. Despite the
results from previous binding studies and the struc-
tural analyses performed with the hRXR complex
[18], the above results suggest that this ligand poorly
protects the hRXR binding site amide hydrogens
from exchange. The reason for this difference is not
immediately obvious, but it may be due either to poor
affinity under the buffering conditions employed or
to interactions occurring at other sites in hRXR.
Conclusions
Binding specificities of various agonists in the human
RXR LBD homodimer were found to be located in the
segments containing the binding residues for the native
1517J Am Soc Mass Spectrom 2006, 17, 1510–1517 LIGAND INTERACTIONS W/HUMAN RXR BY H/D EXCHANGEligand, 9-cis-retinoic acid, by hydrogen/deuterium ex-
change and mass spectrometry. The agonist-specific
alternations in H/D exchange may reflect conforma-
tional specific effects in either amide H-bonding and/or
the accessibility of amide protons to bulk solvent in the
agonist bound tertiary structure in the RXR ho-
modimer. Therefore, the regions in the protein without
direct contact to the agonist exhibit fewer or no changes
in H/D exchange kinetics for the different agonist-
hRXR complexes.
It is worth noting that deuterium exchange kinetic
analysis (Figure 6) provides a rapid and facile single
time-point method for analyzing the structural basis of
protein-ligand binding effects. The analysis associated
with fragment 310–319 and others of hRXR LBD
(Figure 3) provides a dramatic demonstration in the
differences caused by bound agonists on amide hydro-
gen exchange. The application of such a method may be
useful in analyzing the structural interaction between
agonists and retinoid X receptor.
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